



Automated therapy production using 3D printing of isoleucine for treatment of MSUD:

World first single-centre prospective study

Sarah Trenfield, MPharm PhD Researcher, University College London (UCL)
Director of Innovation, FabRx Ltd.





Background

FabRx

- Maple Syrup Urine Disease (MSUD) is a rare, severe metabolic disorder (1 in 185,000 births)
- Deficiency in branched chain alpha-keto acid dehydrogenase (BCKD) complex

Symptoms:

- Sweet-smelling urine
- Vomiting
- Lethargy
- Developmental delay
- If poorly managed= seizures, coma, death




Healthy urine

MSUD urine



Dietary restriction of BCAAs
Strict diet of isoleucine (and other BCAAs)
BCAA blood level monitoring
Patients required to weigh out powders






Study Aims



- Integrate FabRx 3D Printer into a hospital pharmacy setting (Clinic University Hospital, Spain)
- Treat four paediatric patients with personalised isoleucine dosages for MSUD
 - · Conventional capsules vs. printlets
- Evaluate therapy control and medicine acceptability across 6 months of treatment







Xerencia de Xestión Integrada de Santiago de Compostela Santiago de Compostela



Study Design




Patient Recruitment:

4 patients with MSUD (2M, 2F; 3-16 yrs)

		. ()(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
Patient	Gender	Age (Y-M)	Isoleucine dosage (mg)	Rx Instructions
1	М	5y 0m	50	M, W, F
2	F	3y 8m	100	Daily
3	М	16y 1m	200	Daily
4	F	10y 1m	100-150	Daily

Study Design:

Single centre, prospective design



Evaluated for:


- Isoleucine levels (regularly)
- Medicine acceptability (2 weeks) 6





Automatic Compounding Unit OFabRx







Automatic Compounding Unit





100mg

150mg


200mg



6 x flavours 4 x doses

Evaluated for:


(DBS)





Results: Isoleucine Levels






Target = 200μM – 400μM Conclusions = 3D printed formulations enabled a tighter control in target range



Results: PRO Acceptability





- Majority were well accepted Most accepted were:
 - Lemon-yellow, orange



Least accepted were:


Coconut & raspberry





Results: Parent Score





Please rate the participants facial expression:				
Positive face or offers signs of approval	3 points			
No facial expression	2 points			
Signs of distress (grimacing, "scrunching u p" face, squinting, signs of disapproval)	1 point			

- All formulations well accepted
- Capsules, coconut & raspberry least










Conclusions



- Conducted a world first clinical study in comparing FabRx printlets vs. conventional dosage forms
- Printlets enabled a tighter control over isoleucine blood levels
- Majority of flavours / colours well accepted
- Provides further evidence base for use of printed personalised medicines

FabRx GMP Printer



Characteristics:

- User-friendly software
- Portable and versatile printing platform
- Affordable cost
- Ensure drug product quality
- Real-time-release





Acknowledgements



- Alvaro Goyanes (study)
- FabRx team
- Farhan Taherali (UCL)
- Christine Madla (UCL)
- Clinical staff at Clinic University Hospital
 - Dr. Couce
 - Dr. Lamas











Thank you!



